Brucellosis, an infectious disease affecting livestock and humans, is caused by different species of the genus Brucella, which belongs to the alpha-2 subgroup of the Proteobacteria. This subgroup also includes genera normally nonpathogenic for humans, such as Agrobacterium, Rhizobium, and Ochrobactrum (24). In contrast to Brucella species, which infect animals and humans, other alphaproteobacteria usually live in the soil (Ochrobactrum), establish symbiotic relationships with plants (Rhizobium, Mesorhizobium, and Sinorhizobium species) (19), or are phytopathogens (Agrobacterium) (29). These related alphaproteobacteria are not pathogenic for immunocompetent individuals or show only a limited pathogenicity. Human infections with Agrobacterium tumefaciens (Agrobacterium radiobacter) and Ochrobactrum anthropi have been reported almost exclusively to occur in immunocompromised patients or in those with debilitating underlying diseases or undergoing chemotherapy (2, 3, 21). There are no reports of human disease by Rhizobium and other nodule-forming bacteria.
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The close genetic and antigenic relationship between Brucella and nonpathogenic alphaproteobacteria (NPAP) has been revealed by several studies. A total of 1,902 Brucella suis open reading frames are conserved in Mesorhizobium loti, Sinorhizobium meliloti, and Agrobacterium tumefaciens, and 2,408 B. suis open reading frames are conserved in at least one of these three genomes (25) . Similar relationships have been observed between NPAP and Brucella melitensis and Brucella abortus, since the genomes of the last two species are highly similar to that of B. suis (13, 17) .
Few studies have investigated the immunological cross-reactivity between proteins from Brucella and those from related alphaproteobacteria. Velasco et al. (30) found an extensive cross-reactivity between cytosolic proteins from Brucella melitensis and those from Ochrobactrum anthropi and also some cross-reactions at the level of outer membrane proteins and lipopolysaccharide. More recently, we have shown the existence of cross-reactivities between Brucella and other NPAP, including Sinorhizobium meliloti and Agrobacterium tumefaciens (12) . Moreover, we showed that some of these cross-reactivities could potentially be exploited for the development of serological tests for brucellosis based on antigens from NPAP.
Live attenuated Brucella strains are still widely used for the vaccination of animals against brucellosis. While these vaccines have reduced virulence for animals, they still can produce disease in humans (4, 5, 6, 27) . Therefore, large-scale production of such vaccines requires biosafety level 3 facilities (11), which are seldom available in developing countries, where brucellosis is more prevalent. This is one of the reasons that has led many researchers to investigate alternative vaccination strategies for brucellosis, including the use of subunit vaccines based on recombinant proteins (1, 15) or the use of DNA vaccination (9, 20) . Taking into account our previous findings that Brucella antigens and those from NPAP are cross-recognized by the immune system, we hypothesized that the immune response elicited by immunization with the latter could protect mice from Brucella infection. Here we report the results of the studies conducted to address this hypothesis. We show that systemic immunization with heat-killed NPAP or their cytosoluble fractions partially protects mice from Brucella challenge. However, protection levels are higher in mice orally immunized with live NPAP and challenged with Brucella by the oral route than in mice immunized systemically with NPAP.
MATERIALS AND METHODS
Bacteria and culture conditions. Brucella abortus 2308, Brucella melitensis H38, Ochrobactrum anthropi, and Agrobacterium tumefaciens were initially grown in tryptic soy agar (TSA) and expanded in tryptic soy broth to obtain inocula for infections or to prepare heat-killed bacteria. Sinorhizobium meliloti and Mesorhizobium loti were initially grown on solid TY medium (Bacto tryptone, 5 g; yeast extract, 3 g; CaCl 2 , 1.3 g; agar, 7 g in 1 liter of distilled water) and expanded in TY broth (same medium but without agar). All liquid cultures were performed overnight at 28°C with constant agitation.
Antigens. (i) Heat-killed bacteria. After overnight growth, liquid cultures were placed in a water bath at 80°C for 4 h. Samples were plated on TSA or solid TY medium to check for sterility.
(ii) CYTs. Cytosoluble fractions were obtained as described previously (12) . Liquid bacterial cultures were centrifuged at 15,000 ϫ g, and the pellets were washed twice with sterile phosphate-buffered saline (PBS). Bacteria were killed with heat, and the suspensions were centrifuged at 15,000 ϫ g for 10 min and washed three times with 10 mM Tris-HCl (pH 8) (Tris buffer). The cells were suspended in Tris buffer (0.1 g of cells [wet weight] per ml) and disrupted with a French press (SIM-AMINCO-Espectronic Instruments). Bacterial cells were broken by two passages and then digested for 1 h at 37°C with DNase and RNase (10 g/ml). Unbroken cells were separated by centrifugation. Particulate matter was pelleted by centrifugation at 105,000 ϫ g for 4 h, and the resulting supernatant (cytosoluble extract [CYT] ) was stored at Ϫ20°C until use.
Systemic immunization and challenge. Mice (five animals per group) were immunized with three doses (at 2-week intervals) of heat-killed bacteria (1 ϫ 10 9 CFU per dose) mixed with incomplete Freund adjuvant administered subcutaneously in the back or with three doses of CYTs (40 g per dose) administered intraperitoneally. Control groups received PBS by the same routes and at the same times. For the experiment with heat-killed bacteria, the Brucella group was immunized with B. melitensis H38 since this strain is considered a good laboratory reference for evaluating experimental vaccines in mice challenged with B. melitensis or B. abortus (8, 10, 16, 31) . One month after the last immunization, mice were challenged by the intravenous route with 1.3 ϫ 10 4 CFU of live B. abortus 2308. One month after challenge, mice were killed, their spleens were aseptically removed and homogenized, and homogenates were plated on TSA for CFU counting.
Oral immunization and challenge. Two separate experiments of oral immunization were performed. Mice (five animals per group) were inoculated intragastrically at weekly intervals with three doses of live NPAP (1 ϫ 10 8 CFU) or heat-killed B. abortus (HKBA) strain 2308 (1 ϫ 10 8 CFU) or PBS by using an intragastric feeding tube. Twenty days after the last infecting dose, mice were challenged by the same route with live B. abortus 2308 (1.25 ϫ 10 4 ). Mice were killed at 30 days postinfection, and CFU counts in spleens were determined as described above.
Assessment of the antibody response. Blood samples were obtained before each immunization, before challenge, and at sacrifice. At the same time points, mice immunized by the oral route were housed in separate cages, and five fecal pellets were collected from each animal. Fecal samples were mixed with 0.5 ml of extraction buffer (30 mM disodium EDTA, pH 7.6, 100 g/ml soybean trypsin inhibitor, and 10 mg/ml bovine serum albumin in PBS). Pellets were homogenized and centrifuged at 4°C, and supernatants were stored at Ϫ20°C until immunoglobulin A (IgA) measurements were performed.
Specific antibodies to CYT antigens were measured in serum samples and fecal extracts by an indirect enzyme-linked immunosorbent assay. Polystyrene plates (NUNC MaxiSorp) were sensitized at 0.5 g/well with each of the CYTs (obtained as described above). Plates were blocked with 200 l per well of PBS containing 3% skim milk. After a wash with PBS-T (PBS containing 0.05% Tween 20), sera diluted 1:200 were dispensed in PBS-T containing 1% skim milk, while fecal extracts were used undiluted. Specific antibodies were detected with horseradish peroxidase-conjugated antibodies against mouse IgG or mouse IgA (Santa Cruz Biotechnology, Santa Cruz, CA). The reaction was developed by adding ortho-phenylenediamine (2 g in 0.1 M citrate-phosphate buffer containing 0.03% H 2 O 2 ) and was stopped with 4 N H 2 SO 4 . The optical densities were read at 492 nm in a model ⌺960 microplate reader (Metertech Inc., Taiwan).
RESULTS
Protection conferred by immunization with heat-killed bacteria. Subcutaneous immunization with heat-killed bacteria elicited in each case a strong antibody response against CYT antigens of the homologous bacteria (not shown). In most cases, antibody levels were maximal after the second immunization. In mice immunized with nonpathogenic species, the presence of antibodies capable of reacting with Brucella antigens was also tested. As shown in Fig. 1 , cross-reacting antibodies were detected in serum samples obtained at the moment of challenge in all groups of mice immunized with heterologous bacteria. Anti-Brucella antibody levels were significantly augmented in all groups compared to preimmunization levels but tended to be higher in animals immunized with S. meliloti or O. anthropi. These results suggested Protection conferred by immunization with CYTs. As with whole bacteria, intraperitoneal immunization with CYTs from the different species elicited in each case a strong antibody response against the homologous antigens, which in most cases reached maximum levels after the second immunization (not shown). Cross-reacting antibodies against Brucella CYT antigens were detected in serum samples obtained at the moment of challenge in all groups of mice immunized with heterologous bacteria (Fig. 2) . Anti-Brucella antibody levels were significantly augmented in all groups compared to preimmunization levels but were lower in animals immunized with M. loti or A. tumefaciens than in groups receiving S. meliloti, O. anthropi, or B. abortus. Thirty days after challenge with B. abortus, numbers of CFU were significantly lower in the spleens of mice immunized with the different CYT fractions than in mice injected with PBS (Table 2 ). However, the reduction in CFU counts was more significant in mice immunized with CYT from B. abortus or O. anthropi than in mice immunized with fractions from other bacteria. In addition, counts of CFU in mice immunized with B. abortus were significantly lower than those in mice immunized with any other bacteria (P Ͻ 0.01, Dunnett's multiple-comparison test). Anti-Brucella antibodies were detected in all groups at 30 days postchallenge at levels similar to those found at the moment of challenge.
Protection conferred by oral immunization with live bacteria. The experiments described above suggested that immunization with NPAP conferred some protection against Brucella challenge. In addition, for the heterologous species conferring the best protection (O. anthropi), immunization with whole bacteria seemed to protect better than immunization with the CYT fraction. Therefore, we decided to test whether infection with live NPAP would increase the level of protection against Brucella challenge. Taking into account the facts that mucosae are the most common portals of entry for natural Brucella infections and that a systemic infection with a large inoculum of live NPAP could potentially produce adverse effects, the oral route was chosen. Mice infected by intragastric delivery of live bacteria did not exhibit evident physical or behavioral alterations. A group of mice orally immunized with HKBA was also included. At the time of Brucella challenge, mice had a CFU counts in the spleens of mice immunized with NPAP were significantly lower (**, P Ͻ 0.01; *, P Ͻ 0.05) than those of mice receiving PBS (Dunnett's multiple-comparison test).
FIG. 2. Serum reactivity (IgG) against B. abortus cytosolic antigens in mice immunized intraperitoneally with cytosolic fractions from S. meliloti (SM), O. anthropi (OA), M. loti (ML), A. tumefaciens (AT), or B. abortus (BA). Antibodies were measured at challenge with B. abortus 2308 and
at sacrifice for protection evaluation (30 days after challenge). The reactivities of preimmunization sera from all groups were pooled (Pre). *, significantly different from the value for Pre; #, significantly different from the value for BA; NS, not significantly different from reactivities measured at challenge; OD, optical density. developed both IgG and IgA antibodies against the homologous bacteria (not shown). Anti-Brucella IgG levels were significantly higher than preinfection levels in all groups of mice infected with NPAP but were lower in animals infected with A. tumefaciens than in the other NPAP groups (Fig. 3, upper  panel) . Before challenge, animals immunized with HKBA by the oral route exhibited low levels of anti-Brucella IgG in serum, not significantly different from preimmunization levels. After challenge, mice preinfected with A. tumefaciens and mice immunized with HKBA exhibited a significant rise in antiBrucella IgG in serum. Regarding serum IgA against Brucella, no significant increase was found at the time of challenge in mice infected with NPAP or immunized with HKBA. After challenge, however, serum levels of anti-Brucella IgA increased significantly in mice previously infected with O. anthropi and in mice orally immunized with HKBA (Fig. 3, middle panel) . Anti-Brucella IgA was also measured in fecal samples from the same groups of mice. As in the case of serum IgA, fecal levels (Fig. 3, lower panel) . Anti-Brucella IgA levels in serum and feces also tended to increase after challenge in mice preinfected with S. meliloti and A. tumefaciens, but the differences did not reach statistical significance. As shown in Table 3 , Brucella CFU counts in spleens were significantly lower in mice previously infected with NPAP or immunized with HKBA than in the PBS controls, with no significant difference among the NPAP groups. In addition, counts of CFU in mice immunized with HKBA were significantly lower than those in mice immunized with A. tumefaciens (P Ͻ 0.05, Dunnett's multiple-comparison test). Protection levels tended to be higher than those obtained with the same bacteria in the experiments of systemic immunization and challenge, and the difference was especially evident for A. tumefaciens and S. meliloti.
DISCUSSION
Vaccination of animals to prevent brucellosis is currently performed with live attenuated strains of Brucella, including B. melitensis Rev1, B. abortus S19, and B. abortus RB51. However, these vaccines are unsafe for humans, and several cases of human illness by accidental inoculation, inhalation, or splashing have been reported. Different strategies have been explored to develop safer vaccines against brucellosis (1, 9, 15, 20) . The goal of the present study was to assess whether administration of whole NPAP or their subcellular fractions through different routes could protect mice from a subsequent challenge with live B. abortus. The rationale behind this strategy was that the immune response elicited against antigens or antigenic determinants shared by NPAP and Brucella would confer some protection against challenge with B. abortus.
Previous studies have assessed the reciprocal cross-protection conferred by immunization with bacterial species from different genera. The rationale behind most of these studies has been the similarity between the lipid A region of the lipopolysaccharides of different gammaproteobacteria (7, 23) . Thus, cross-protection was assessed, for example, for Proteus spp. versus Providencia spp. (26) , the Escherichia coli J5 mutant versus Haemophilus influenzae type b (22) , and the Salmonella enterica serovar Minnesota Re mutant versus Pseudomonas aeruginosa (28) . To the best of our knowledge, however, no studies of cross-protection between heterologous genera have been performed with the specific aim of reducing the biosafety conditions required for the production of live vaccines against highly hazardous agents, such as Brucella spp., and the risks inherent to the use of such vaccines.
To the best of our knowledge, there is only one previous study that explored the use of an NPAP to prevent brucellosis. He et al. (18) The results of the current study show that, in general, the NPAP assayed confer some degree of protection against Brucella challenge. However, O. anthropi cells or antigens conferred the highest levels of protection for all the immunization strategies evaluated. A notable finding was that, for all the nonpathogenic species, the protection level obtained with orally administered viable bacteria against challenge by the same route was higher than that attained with systemic immunization with whole bacteria or CYT antigens. This difference was especially evident for immunizations with A. tumefaciens and S. meliloti. This result is especially important since the oral route is one of the most frequent portals of entry for Brucella species both in humans and animals. Therefore, a potential strategy for protecting animals from Brucella infection could be to add these NPAP in appropriate quantities to the usual diet or the drinking water of such animals. Further studies will be needed to explore the efficacy of these strategies. Vaccination with a live attenuated Brucella suis strain (S2) administered through drinking water has been used in China since the beginning of the 1970s for sheep, goats, and other animals and has been proven to confer up to 3 years of protection (14) . As with other Brucella vaccine strains, however, this strain is not innocuous for humans and must be produced under biosafety level 3 conditions. An important implication of the results obtained with oral immunization is that no adjuvants were required. In the study by He et al., no protection was obtained with systemic immunization with live O. anthropi in the absence of adjuvants. In the current study, oral vaccination with live O. anthropi without adjuvants conferred a protection level of 0.88 to 0.96 log 10 units.
While this study did not explore the immune mechanisms involved in protection against Brucella challenge, the finding of anti-Brucella antibodies in mice immunized or infected with NPAP indicates that these animals had developed an immune response capable of recognizing Brucella antigens. Particularly noticeable were the increases in serum and fecal IgA levels upon Brucella challenge of mice previously infected with O. anthropi by the oral route. In contrast, no increase in antiBrucella IgG levels was detected after challenge of animals immunized with heat-killed bacteria or CYT fractions. Nevertheless, a boost of IgG levels may have occurred early after challenge, and by the time the animals were examined again (30 days postchallenge), antibody levels may have returned to prechallenge levels. a CFU counts in the spleens of mice immunized with NPAP or HKBA were significantly lower (**, P Ͻ 0.01; *, P Ͻ 0.05) than those of mice receiving PBS (Dunnett's multiple-comparison test).
Experiments of oral immunization with live bacteria included a control group of mice immunized with HKBA. Before challenge, this group exhibited low levels of anti-Brucella antibodies in both their sera and their feces. This result is not surprising if we take into account the fact that these animals received killed bacteria by the oral route in the absence of adjuvants. Upon oral challenge with live B. abortus, in contrast, this group exhibited a marked increase in anti-Brucella antibody levels. This is the first study to assess cross-protection as a strategy for reducing the risks associated with the production and handling of live vaccines against hazardous agents. Our results suggest that immunization with NPAP, especially O. anthropi, confers some degree of protection against Brucella infection. Inoculation of live NPAP seems to confer higher levels of protection than immunization with heat-killed bacteria or CYT fractions. However, even in this case, the protection obtained is lower than that conferred by the homologous species. New studies with other immunization protocols will be needed to assess whether protection conferred by NPAP immunization can be improved further.
